EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance

Benoit Immordino, Mafalda Angelica Rocco, Annalisa Comandatore, Gaby van der Zee, Mahrou Vahabi, Luca Morelli, Elisa Giovannetti

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101408 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Benoit Immordino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Sciences, Sant'Anna School of Advanced Studies, Pisa 56127, Italy; Fondazione Pisana per la Scienza ONLUS, San Giuliano Terme 56017…. Hauptthemen laut MEDLINE: Receptor Protein-Tyrosine Kinases, Drug Resistance, Neoplasm, Biomarkers, Tumor, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Nadia Valsecchi, Italian Association for Cancer Research, European Cooperation in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to therapy is a major driver of the dismal prognosis of pancreatic ductal adenocarcinoma (PDAC), which is projected to become the second leading cause of cancer-related death by 2030. The lack of reliable biomarkers for early detection and the rapid emergence of therapeutic resistance underscore an urgent need for strategies capable of improving patient stratification and overcoming treatment failure. In this context, the receptor tyrosine kinase AXL has gained increasing attention as a mediator of PDAC progression, sustaining tumor cell survival and plasticity while fostering an immunosuppressive, fibrotic microenvironment, that collectively fuels resistance to both cytotoxic and targeted therapies. In this review, we critically evaluate the therapeutic landscape of AXL inhibition in PDAC. We discuss the spectrum of pharmacological approaches under investigation, including small-molecule inhibitors, monoclonal antibodies, and ligand-blocking agents, alongside emerging modalities such as antibody-drug conjugates, bispecific formats, and CAR-T cell platforms, emphasizing both their promise and the persistent barriers of limited tumor penetration and stromal resistance. Furthermore, we highlight the growing interest in AXL as a circulating biomarker, with potential applications in early patient selection, dynamic treatment monitoring, and prediction of resistance. By integrating mechanistic insights with translational advances, this review outlines both the opportunities and the barriers that will shape the future of AXL-directed strategies in PDAC and their potential to address current gaps in therapeutic resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor Protein-Tyrosine KinasesDrug Resistance, NeoplasmBiomarkers, TumorPancreatic NeoplasmsProto-Oncogene ProteinsCarcinoma, Pancreatic DuctalAntineoplastic AgentsHumansAxl Receptor Tyrosine KinaseTumor MicroenvironmentMolecular Targeted TherapyAnimalsProtein Kinase Inhibitors

Stichwörter der Autor:innen

AXL receptor tyrosine kinaseAntibody-drug conjugates (ADCs)Chimeric antigen receptor T cells (CAR-T cells)Circulating biomarkerDrug resistanceMonoclonal antibodies (mAbs)Pancreatic ductal adenocarcinoma (PDAC)Tumor microenvironment (TME)Tyrosine kinase inhibitors (TKIs)

Substanzen

Axl Receptor Tyrosine KinaseReceptor Protein-Tyrosine KinasesBiomarkers, TumorAXL protein, humanProto-Oncogene ProteinsAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Institute of Life Sciences, Sant'Anna School of Advanced Studies, Pisa 56127, Italy; Fondazione Pisana per la Scienza ONLUS, San Giuliano Terme 56017, Italy.
  • Institute of Life Sciences, Sant'Anna School of Advanced Studies, Pisa 56127, Italy; Fondazione Pisana per la Scienza ONLUS, San Giuliano Terme 56017, Italy; Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan…
  • Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, Amsterdam 1081HV, the Netherlands; General Surgery, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pi…
  • Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, Amsterdam 1081HV, the Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, Amsterdam 1081HV, the Netherlands; Laboratory of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam 10…
  • General Surgery, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Paradisa 2, Pisa 56125, Italy.

Förderung

  • Fondazione Nadia Valsecchi
  • Italian Association for Cancer Research
  • European Cooperation in Science and Technology
  • KWF Dutch Cancer Society
  • Fondazione Pisa

Zitieren

APA

Immordino, B., Rocco, M. A., Comandatore, A., van der Zee, G., Vahabi, M., Morelli, L., & Giovannetti, E. (2026). The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101408

Vancouver

Immordino B, Rocco MA, Comandatore A, van der Zee G, Vahabi M, Morelli L, et al. The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101408

BibTeX
@article{Immordino2026,
  author = {Immordino, Benoit and Rocco, Mafalda Angelica and Comandatore, Annalisa and van der Zee, Gaby and Vahabi, Mahrou and Morelli, Luca and Giovannetti, Elisa},
  title = {The emerging role of AXL in pancreatic cancer: Biomarker potential and therapeutic targeting to counteract drug resistance},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101408}
}
Kostenlos starten →